Weijing Feng1,2,3, Zhibin Li4, Wenjie Guo1,2,3, Xianglin Fan1,2,3, Feiran Zhou1,2,3, Kun Zhang4, Caiwen Ou5,2,3, Feifei Huang6, Minsheng Chen5,2,3. 1. Department of Cardiology, Laboratory of Heart Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China. 2. Guangdong Provincial Key Laboratory of Shock and Microcirculation, Guangzhou, China. 3. Sino-Japanese Cooperation Platform for Translational Research in Heart Failure, Guangzhou, China. 4. Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. 5. Department of Cardiology, Laboratory of Heart Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China gzminsheng@vip.163.com oucaiwen@smu.edu.cn beier504@163.com. 6. Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China gzminsheng@vip.163.com oucaiwen@smu.edu.cn beier504@163.com.
Abstract
OBJECTIVE: To investigate whether intraindividual variability of fasting glucose (FG) in young adulthood is associated with coronary artery calcification (CAC) progression in middle age. RESEARCH DESIGN AND METHODS: We included 2,256 CARDIA (Coronary Artery Risk Development Study in Young Adults) participants with CAC assessment by computed tomography scanner at baseline (2000-2001) and 10 years later (2010-2011). CAC progression was assessed for each individual as the difference of logarithmic CAC scores at follow-up and baseline (log[CAC (follow-up) + 1] - log[CAC (baseline) + 1]). FG variability was defined by the coefficient of variation about the mean FG (FG-CV), the SD of FG (FG-SD), and the average real variability of FG (FG-ARV) during the 10-year follow-up. We investigated the association between FG variability and CAC progression with adjustment for demographics, clinical risk factors, mean FG level, change in FG level, diabetes incidence, and medication use. RESULTS: After multivariable adjustment, 1-SD increment in FG-CV was associated with worse progression of CAC as demonstrated as percent change in CAC, with incident CAC 5.9% (95% CI 1.0, 10.7) and any CAC progression 6.7% (95% CI 2.3, 11.1) during 10 years. Similar findings were also observed in FG-SD and FG-ARV. CONCLUSIONS: Higher FG variability during young adulthood was associated with greater CAC progression in middle age, suggesting its value in predicting risk for subclinical coronary artery diseases.
OBJECTIVE: To investigate whether intraindividual variability of fasting glucose (FG) in young adulthood is associated with coronary artery calcification (CAC) progression in middle age. RESEARCH DESIGN AND METHODS: We included 2,256 CARDIA (Coronary Artery Risk Development Study in Young Adults) participants with CAC assessment by computed tomography scanner at baseline (2000-2001) and 10 years later (2010-2011). CAC progression was assessed for each individual as the difference of logarithmic CAC scores at follow-up and baseline (log[CAC (follow-up) + 1] - log[CAC (baseline) + 1]). FG variability was defined by the coefficient of variation about the mean FG (FG-CV), the SD of FG (FG-SD), and the average real variability of FG (FG-ARV) during the 10-year follow-up. We investigated the association between FG variability and CAC progression with adjustment for demographics, clinical risk factors, mean FG level, change in FG level, diabetes incidence, and medication use. RESULTS: After multivariable adjustment, 1-SD increment in FG-CV was associated with worse progression of CAC as demonstrated as percent change in CAC, with incident CAC 5.9% (95% CI 1.0, 10.7) and any CAC progression 6.7% (95% CI 2.3, 11.1) during 10 years. Similar findings were also observed in FG-SD and FG-ARV. CONCLUSIONS: Higher FG variability during young adulthood was associated with greater CAC progression in middle age, suggesting its value in predicting risk for subclinical coronary artery diseases.
Authors: T Nishikawa; D Edelstein; X L Du; S Yamagishi; T Matsumura; Y Kaneda; M A Yorek; D Beebe; P J Oates; H P Hammes; I Giardino; M Brownlee Journal: Nature Date: 2000-04-13 Impact factor: 49.962
Authors: Kiarri N Kershaw; Whitney R Robinson; Penny Gordon-Larsen; Margaret T Hicken; David C Goff; Mercedes R Carnethon; Catarina I Kiefe; Stephen Sidney; Ana V Diez Roux Journal: JAMA Intern Med Date: 2017-07-01 Impact factor: 21.873
Authors: N Sarwar; P Gao; S R Kondapally Seshasai; R Gobin; S Kaptoge; E Di Angelantonio; E Ingelsson; D A Lawlor; E Selvin; M Stampfer; C D A Stehouwer; S Lewington; L Pennells; A Thompson; N Sattar; I R White; K K Ray; J Danesh Journal: Lancet Date: 2010-06-26 Impact factor: 202.731
Authors: Amir A Mahabadi; Nils Lehmann; Hagen Kälsch; Tim Robens; Marcus Bauer; Iryna Dykun; Thomas Budde; Susanne Moebus; Karl-Heinz Jöckel; Raimund Erbel; Stefan Möhlenkamp Journal: JACC Cardiovasc Imaging Date: 2014-09
Authors: Richard A Kronmal; Robyn L McClelland; Robert Detrano; Steven Shea; João A Lima; Mary Cushman; Diane E Bild; Gregory L Burke Journal: Circulation Date: 2007-05-14 Impact factor: 29.690
Authors: Irene E Schauer; Janet K Snell-Bergeon; Bryan C Bergman; David M Maahs; Adam Kretowski; Robert H Eckel; Marian Rewers Journal: Diabetes Date: 2010-10-26 Impact factor: 9.461
Authors: April P Carson; Michael W Steffes; J Jeffrey Carr; Yongin Kim; Myron D Gross; Mercedes R Carnethon; Jared P Reis; Catherine M Loria; David R Jacobs; Cora E Lewis Journal: Diabetes Care Date: 2014-10-16 Impact factor: 17.152